| UniProt/SwissProt ID: | PDC6I_HUMAN |
| Description: | programmed cell death 6 interacting protein [Source:HGNC Symbol;Acc:8766] |
| Location: | chr3 p22.3 |
| Node attribute: | substrate |
| Phosphorylation site |
| Position | PhosphoPeptide | Catalytic kinase | Source |
|---|---|---|---|
| Y258 | QANAEyHQSIL | BRO1 | PhosphoSitePlus |
| Y319 | DNDFIyHDRVP | SRC | HPRD |
| S730 | PAYQSsPAGGH | PhosphoSitePlus; HPRD; phosphoELM | |
| S718 | IAREPsAPSIP | PhosphoSitePlus | |
| Y39 | EEQAQyCRAAE | BRO1 | PhosphoSitePlus |
| T738 | GGHAPtPPTPA | PhosphoSitePlus; HPRD; phosphoELM | |
| Y294 | SRYDEyVNVKD | BRO1 | PhosphoSitePlus |
| S366 | VSVQQsLAAYN | BRO1 | PhosphoSitePlus |
| T741 | APTPPtPAPRT | PhosphoSitePlus; HPRD; phosphoELM | |
| Y370 | QSLAAyNQRKA | BRO1 | PhosphoSitePlus |
| S729 | TPAYQsSPAGG | HPRD; phosphoELM | |
| S712 | KDLQQsIAREP | PhosphoSitePlus; HPRD | |
| Y727 | IPTPAyQSSPA | PhosphoSitePlus; HPRD; phosphoELM | |
| T724 | APSIPtPAYQS | PhosphoSitePlus | |
| Y485 | PSNELyKPLRA | ALIX_LYPXL_bnd | PhosphoSitePlus |
| T186 | PDTVGtLSLIM | BRO1 | PhosphoSitePlus |
| Y223 | NQAADyFGDAF | BRO1 | PhosphoSitePlus |
| Y319 | DNDFIyHDRVP | BRO1 | PhosphoSitePlus |
| Dephosphorylation site |
| PDC6I_HUMAN do not have dephosphorylation site. |
| Mutation site |
| Ensembl ID | Variation | Source | Cancer name | Pubmed |
|---|---|---|---|---|
| ENSP00000307387 | L308V | COSMIC | Ovarian Cancer | 21720365 | ENSP00000307387 | A98V | COSMIC | Melanoma | ENSP00000307387 | D591G | COSMIC | Central Nervous System Neoplasms | 21817013 |
| Differential expressed protein |
| Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
|---|---|---|---|---|---|---|
| ENSP00000307387 | Ovarian Cancer | Treatment (cisplatin-sensitive vs. cisplatin-resistant) | cell line | Up | 13 | 16319398 | ENSP00000307387 | Hepatocellular Carcinoma | Metastasis | cell line | Up | 1.9 | 19016532 | ENSP00000307387 | Breast Cancer | Treatment (tamoxifen-sensitive vs. tamoxifen-resistant) | tissue | Down | 0.45 | 19329653 | ENSP00000307387 | Breast Cancer | Normal vs. Cancer | cell line | Up | 1.9 | 20052998 | ENSP00000307387 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.93 | 20052998 | ENSP00000307387 | Breast Cancer | Metastasis | cell line | Down | 0.5 | 20052998 | ENSP00000307387 | Nonmelanoma | Normal vs. Cancer | cell line | Down | 0.7 | 19243805 | ENSP00000307387 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Up | 1.3 | 19714814 |
| Hyperphosphorylation site |
| PDC6I_HUMAN do not have hyperphosphorylation site. |
| Direct Interaction Pair |
| Source | Target | Relationship | Resource |
|---|---|---|---|
| SRC_HUMAN | PDC6I_HUMAN | kinase -> substrate | HPRD |
| Function Annotation |
| KEGG Pathway |
| KEGG ID | Pathway |
|---|---|
| hsa04144 | Endocytosis |
| Gene Ontology |
| GO ID | GO_Term | Evidence | Ontology |
|---|---|---|---|
| GO:0005737 | cytoplasm | IDA | cellular_component |
| GO:0005737 | cytoplasm | IEA | cellular_component |
| GO:0017124 | SH3 domain binding | IEA | molecular_function |
| GO:0051301 | cell division | IEA | biological_process |
| GO:0005815 | microtubule organizing center | IEA | cellular_component |
| GO:0046983 | protein dimerization activity | IEA | molecular_function |
| GO:0005515 | protein binding | IEA | molecular_function |
| GO:0007049 | cell cycle | IEA | biological_process |
| GO:0019048 | virus-host interaction | IEA | biological_process |
| GO:0006915 | apoptotic process | IEA | biological_process |
| GO:0005829 | cytosol | IEA | cellular_component |
| GO:0005515 | protein binding | IPI | molecular_function |
| GO:0048306 | calcium-dependent protein binding | IPI | molecular_function |
| GO:0042470 | melanosome | IEA | cellular_component |
| GO:0015031 | protein transport | IEA | biological_process |